Opinion|Videos|September 18, 2024
Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib
Medical experts compare the efficacy and safety of new therapies, including FTD/TPI plus bevacizumab and fruquintinib, to regorafenib for metastatic colorectal cancer.
Advertisement
Episodes in this series
Video content above is prompted by the following:
How do these new therapy options (FTD/TPI plus bevacizumab, fruquintinib) compare with regorafenib in terms of efficacy and safety?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Bringing CAR T-Cell Therapy Into Community Cancer Centers
2
The True Cost of Running a Community CAR T-Cell Program
3
Texas Hospitals Lose $27 Million a Day in Medicaid Funding Dispute
4
Tozorakimab Cuts COPD Exacerbations Up to 34% in Phase 3 Trials
5